Narcolepsy drugs market size to increase by USD 1.60 billion from 2021 to 2026: Alkermes Public Ltd. Co. and Avadel Pharmaceuticals plc among key vendors - Technavio

Rhea-AI Summary

The narcolepsy drugs market is projected to grow by USD 1.60 billion from 2021 to 2026, at a CAGR of 9.1%, as per a Technavio report. Key growth drivers include rising product launches, increasing narcolepsy incidences, and enhanced research efforts for understanding the condition. The North America region is expected to contribute 44% of the market growth, particularly in the US and Canada. Noteworthy vendors include Avadel Pharmaceuticals with its FT218 tablets. Challenges such as low awareness and stringent regulations may impede growth. The market will see key trends like advancements in narcolepsy treatment and a growing preference for combination therapies.

Positive

• Projected market growth of USD 1.60 billion from 2021 to 2026.
• CAGR of 9.1% indicates strong market demand.
• 44% of market growth expected from North America.

Negative

• Challenges include low awareness of narcolepsy symptoms.
• Stringent regulations may hinder market entry and innovation.

NEW YORK, April 12, 2023 /PRNewswire/ -- The narcolepsy drugs market size is forecasted to increase by USD 1.60 billion from 2021 to 2026, at a CAGR of 9.1%, according to the recent market study by Technavio. The growth of the market will be driven by the rising number of product launches and clinical trials, the increasing incidence of narcolepsy in adults, and the growing number of studies to understand the cause and treatment of narcolepsy. Charts & data tables about the market and forecast period (2022-2026) have been covered in this report. Download the sample report

Vendor analysis: Vendor offerings -

Technavio has extensively analyzed 15 major vendors, including Alkermes Public Ltd. Co., Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., BIOPROJET, Cadila Pharmaceuticals Ltd., Don Valley Pharma, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals Plc, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Somacare, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd. The key offerings of some of these vendors are listed below:

• Alkermes Public Ltd. Co. - The company offers narcolepsy drugs such as ALKS 2680 tablets.
• Avadel Pharmaceuticals plc - The company offers narcolepsy drugs such as FT218 tablets.
• Axsome Therapeutics Inc. - The company offers narcolepsy drugs such as Sunosi tablets.
• BIOPROJET - The company offers narcolepsy drugs such as Wakix, which is a histamine H3 receptor antagonist.
• Jazz Pharmaceuticals Plc - The company offers narcolepsy drugs such as Xywav tablets.

Get a holistic overview of the market vendors by industry experts to evaluate and develop growth strategies. Download the sample

Key benefits for industry players & stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Market Segmentation:

The narcolepsy drugs market is segmented by type (narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Based on type, the narcolepsy with cataplexy segment will account for a significant share of the market growth during the forecast period. Narcolepsy with cataplexy generally starts during a patient's teenage or young adulthood period and continues throughout the lifetime. According to pathophysiological studies, the early loss of neurons in the hypothalamus is one of the main causes of this disease. To treat the disease, stimulant drugs are prescribed to suppress daytime sleepiness, and antidepressants are prescribed for cataplexy. Gamma-hydroxybutyrate is used to treat both symptoms. Therefore, the rising number of cases of narcolepsy with cataplexy will boost the growth of the segment during the forecast period.

Based on geography, North America will account for 44% of the market's growth during the forecast period. The US and Canada are the key contributors to the narcolepsy drugs market growth in the region. However, market growth in this region will be slower than the growth of the market in Asia. Factors such as the high per capita pharmaceutical expenditure will drive the narcolepsy drugs market growth in North America during the forecast period.

Market Dynamics:

Key drivers:

• Rising number of product launches and clinical trials
• Increasing incidence of narcolepsy in adults
• Growing number of studies to understand the cause and treatment of narcolepsy

The rising number of narcolepsy cases has encouraged vendors to launch new drugs to meet the demand. For instance, in July 2020, Jazz Pharmaceuticals announced that it had received approval from the Food and Drug Administration (FDA) for Xywav, which is an oral solution that treats cataplexy or excessive daytime sleepiness in patients aged seven and above. In 2021, Avadel Pharmaceuticals's new drug application (NDA) for an investigational agent, FT218, was accepted by the FDA for the treatment of excessive daytime sleepiness and cataplexy among adults with narcolepsy. In 2021, a researcher at Stanford University illustrated a Phase 3 study, according to which an extended-release version of sodium oxybate reduces daytime sleepiness and improves muscle weakness among narcolepsy patients. These factors are expected to drive market growth during the forecast period.

Major trends:

• Advancement in narcolepsy treatment
• Increasing demand for non-pharmacological therapies
• Combination treatments for narcolepsy

Narcolepsy symptoms are different in each patient. Hence, treatments must be customized, depending on symptoms, body types, and other factors. Narcolepsy can be treated with medication and lifestyle changes. Currently, the available treatments improve the symptoms that negatively impact the quality of life of patients. The treatments work in different ways. For instance, drugs that promote stimulants and wakefulness, such as Provigil (modafinil) and Nuvigil (armodafinil) Xyrem (sodium oxybate), and Effexor (venlafaxine), reduce the periodic occurrence of cataplexy attacks. These factors will fuel the market growth during the forecast period.

Key challenges:

• Lack of awareness
• Stringent regulations
• Lack of proper diagnosis and management of narcolepsy

The symptoms of narcolepsy are often confused with many psychiatric and neurologic disorders due to a lack of awareness. As a result, doctors may prescribe antiepileptics and psychotropics, which can adversely impact the health of patients. Only 9% of primary care physicians (PCPs) and 42% of sleep specialists admitted that they were comfortable diagnosing the disorder. Moreover, most narcolepsy patients are undiagnosed, as the symptoms are misinterpreted. Therefore, low awareness about narcolepsy will hinder the market growth during the forecast period.

To get detailed insights about market dynamics, buy the report

What are the key data covered in this narcolepsy drugs market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the narcolepsy drugs market between 2022 and 2026
• Precise estimation of the size of the narcolepsy drugs market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the narcolepsy drugs market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of narcolepsy drugs market vendors

Related Reports:

The antidepressants drugs market size is expected to increase by USD 5.22 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. Furthermore, this report extensively covers antidepressants drugs market segmentations by disease type (major compulsive disorder, obsessive compulsive disorder, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

The global migraine drugs market size is estimated to grow by USD 1 billion between 2021 to 2026, accelerating at a CAGR of 5.74%. This migraine drugs market report extensively covers market segmentation by end-user (hospitals, retail, and online), type (preventive and abortive), and geography (North America, Europe, Asia, and Rest of World (ROW)).

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

Narcolepsy Drugs Market Scope
Report Coverage	Details
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 9.1%
Market growth 2022-2026	USD 1.60 billion
Market structure	Fragmented
YoY growth 2021-2022 (%)	8.5
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 44%
Key countries	US, Canada, Germany, UK, and France
Competitive landscape	Leading vendors, market positioning of vendors, competitive strategies, and industry risks
Key companies profiled	Alkermes Public Ltd. Co., Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., BIOPROJET, Cadila Pharmaceuticals Ltd., Don Valley Pharma, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals Plc, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Somacare, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd.
Market dynamics	Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio Health Care Market reports

Table of contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments 
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type 
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 Narcolepsy with cataplexy - Market size and forecast 2021-2026 
• Exhibit 28: Chart on Narcolepsy with cataplexy - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Narcolepsy with cataplexy - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Narcolepsy with cataplexy - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Narcolepsy with cataplexy - Year-over-year growth 2021-2026 (%)

• 5.4 Narcolepsy without cataplexy - Market size and forecast 2021-2026 
• Exhibit 32: Chart on Narcolepsy without cataplexy - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Narcolepsy without cataplexy - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Narcolepsy without cataplexy - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Narcolepsy without cataplexy - Year-over-year growth 2021-2026 (%)

• 5.5 Secondary narcolepsy - Market size and forecast 2021-2026
• Exhibit 36: Chart on Secondary narcolepsy - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Secondary narcolepsy - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Secondary narcolepsy - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Secondary narcolepsy - Year-over-year growth 2021-2026 (%)

• 5.6 Market opportunity by Type 
• Exhibit 40: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 42: Chart on Market share by geography 2021-2026 (%)
• Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 44: Chart on Geographic comparison
• Exhibit 45: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 France - Market size and forecast 2021-2026
• Exhibit 78: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on France - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 83: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 85: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 86: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 87: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 88: Matrix on vendor position and classification

• 10.3 Alkermes Public Ltd. Co. 
• Exhibit 89: Alkermes Public Ltd. Co. - Overview
• Exhibit 90: Alkermes Public Ltd. Co. - Product / Service
• Exhibit 91: Alkermes Public Ltd. Co. - Key news
• Exhibit 92: Alkermes Public Ltd. Co. - Key offerings

• 10.4 Avadel Pharmaceuticals plc 
• Exhibit 93: Avadel Pharmaceuticals plc - Overview
• Exhibit 94: Avadel Pharmaceuticals plc - Business segments
• Exhibit 95: Avadel Pharmaceuticals plc - Key news
• Exhibit 96: Avadel Pharmaceuticals plc - Key offerings
• Exhibit 97: Avadel Pharmaceuticals plc - Segment focus

• 10.5 Axsome Therapeutics Inc. 
• Exhibit 98: Axsome Therapeutics Inc. - Overview
• Exhibit 99: Axsome Therapeutics Inc. - Product / Service
• Exhibit 100: Axsome Therapeutics Inc. - Key offerings

• 10.6 BIOPROJET 
• Exhibit 101: BIOPROJET - Overview
• Exhibit 102: BIOPROJET - Product / Service
• Exhibit 103: BIOPROJET - Key offerings

• 10.7 Jazz Pharmaceuticals Plc 
• Exhibit 104: Jazz Pharmaceuticals Plc - Overview
• Exhibit 105: Jazz Pharmaceuticals Plc - Product / Service
• Exhibit 106: Jazz Pharmaceuticals Plc - Key news
• Exhibit 107: Jazz Pharmaceuticals Plc - Key offerings

• 10.8 Shionogi and Co. Ltd. 
• Exhibit 108: Shionogi and Co. Ltd. - Overview
• Exhibit 109: Shionogi and Co. Ltd. - Product / Service
• Exhibit 110: Shionogi and Co. Ltd. - Key offerings

• 10.9 Somacare 
• Exhibit 111: Somacare - Overview
• Exhibit 112: Somacare - Product / Service
• Exhibit 113: Somacare - Key offerings

• 10.10 Takeda Pharmaceutical Co. Ltd. 
• Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Overview
• Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 116: Takeda Pharmaceutical Co. Ltd. - Key news
• Exhibit 117: Takeda Pharmaceutical Co. Ltd. - Key offerings

• 10.11 Teva Pharmaceutical Industries Ltd. 
• Exhibit 118: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 119: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 120: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 121: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 122: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 XWPharma Ltd. 
• Exhibit 123: XWPharma Ltd. - Overview
• Exhibit 124: XWPharma Ltd. - Product / Service
• Exhibit 125: XWPharma Ltd. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 126: Inclusions checklist
• Exhibit 127: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 128: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 129: Research methodology
• Exhibit 130: Validation techniques employed for market sizing
• Exhibit 131: Information sources

• 11.5 List of abbreviations 
• Exhibit 132: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/narcolepsy-drugs-market-size-to-increase-by-usd-1-60-billion-from-2021-to-2026-alkermes-public-ltd-co-and-avadel-pharmaceuticals-plc-among-key-vendors---technavio-301794599.html

SOURCE Technavio

FAQ

What is the expected growth of the narcolepsy drugs market by 2026?

The narcolepsy drugs market is projected to grow by USD 1.60 billion from 2021 to 2026.

What is the CAGR for the narcolepsy drugs market during the forecast period?

The CAGR for the narcolepsy drugs market is expected to be 9.1%.

Which region is expected to contribute the most to the narcolepsy drugs market?

North America is expected to contribute 44% of the market growth.

Who are the key vendors in the narcolepsy drugs market?

Key vendors include Alkermes and Avadel Pharmaceuticals.

What challenges does the narcolepsy drugs market face?

The market faces challenges such as low awareness and stringent regulations.